Bellerophon Therapeutics, Inc. (BLPH) has seen some recent movement in the marketplace and its stock closed trading at $15.90 yesterday. Traders are starting to take interest of BLPH as the stock traded as high as $16.66 and as low as $15.50 in the previous market trading day.

Bellerophon Therapeutics, Inc. (BLPH) average trading volume is 970.68K. However, in the previous market trading day Bellerophon Therapeutics, Inc. (BLPH) exchanged 163,065 shares. The 1st support level on BLPH is $16.00 and the 1st upside resistance level on BLPH is $25.62. BLPH 50-day moving average is $11.94 and BLPH two hundred day moving average is $7.57.

Bellerophon Therapeutics, Inc. (BLPH) most current performance has been indicated by the recent movement in BLPH stock. BLPH has performed 65.61% over the past 30 days, BLPH has performed 217.33% over the past 90 days and BLPH has shown 78.71% over the past 365 days. Bellerophon Therapeutics, Inc. (BLPH) has a 52 week range of $3.19 to $26.00. Bellerophon Therapeutics, Inc. (BLPH) is trading 422.93% from its 52 week low and -35.92% from its 52 week high. Bellerophon Therapeutics, Inc. (BLPH) is showing a 2.52% short float showing the amount short in the float.

BLPH has 5.78M shares outstanding and 4.41M shares in the float. Bellerophon Therapeutics, Inc. (BLPH) presently has a market cap of $96.29M and income of $-13.30M. The EPS next quarter for BLPH is -0.75 and projected EPS net year is 34.20%. The market cap of Bellerophon Therapeutics, Inc. (BLPH) at $96.29M signifies how many Traders own shares of BLPH and is based off the last price ($15.90) of BLPH and the amount of shares outstanding (5.78M) with Bellerophon Therapeutics, Inc. (BLPH).

Bellerophon Therapeutics, Inc. (BLPH) has total cash (mrq) of 9.87M, total cash per share (mrq) of 1.61, total debt of BLPH stands at 2.32M and total debt/equity (mrq) is 64.52. Bellerophon Therapeutics, Inc. (BLPH) operating cash flow (ttm) is -12.94M and BLPH leveraged free cash flow (ttm) is -8.79M.

BLPH is trading 22.53% above (bullish) its SMA20, 59.14% above (bullish) its SMA50 and 110.22% above (bullish) its SMA200.

Recent News:

In recent news, on May 4, 2020, it was announced, Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference. In this news it stated, Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer of Bellerophon, will participate in a COVID-19 panel at the upcoming Infectious Disease Virtual Conference presented by Maxim Group on Tuesday, May 5, 2020, at 3:45 PM ET.

About Bellerophon Therapeutics, Inc. (BLPH):

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage.